MedicarePartD.guide

A non-government resource built from CMS public data

Bimzelx on SilverScript Choice (S5601-022)

bimekizumab

Covered, with prior authorization required.

Tier 5 (specialty tier). Quantity limit of 4 per 28 days.

$8,217.12
Patient pays / month, after deductible
$8,678.37
Patient pays / month, before the $615.00 deductible
Not offered
Patient pays / 90 days by mail
$0
After the yearly $2,100.00 out-of-pocket cap

BIMZELX 160 mg/mL Injection, Solution at a preferred retail pharmacy, from the plan's negotiated price of $32,868.49 for a month. Other covered strengths are listed below.

Prior authRequired on all 4 covered forms· The plan decides within 72 hours, or 24 if expedited· If denied, the prescriber can ask the plan to reconsider (an appeal)
All 4 covered strengths and forms
FormTierPatient pays / monthLimits
BIMZELX 160 mg/mL Injection, Solution5$8,217.12PA · 4 per 28 days
BIMZELX 160 mg/mL Injection, Solution5$8,217.12PA · 4 per 28 days
BIMZELX 320 mg/2mL Injection, Solution5$8,711.20PA · 4 per 28 days
BIMZELX 320 mg/2mL Injection, Solution5$8,711.20PA · 4 per 28 days

Other IL-17 and IL-23 biologics on this plan

Verify with the plan before prescribing or filling. Member services: (866)235-5660. Data from the CMS 2026 Part D formulary and pricing files. Full plan details

Plan ID s5601-022